Category Archives: Cell Biology

Regulation and dynamics of force transmission at individual cell-matrix adhesion bonds – Science Advances

Abstract

Integrin-based adhesion complexes link the cytoskeleton to the extracellular matrix (ECM) and are central to the construction of multicellular animal tissues. How biological function emerges from the tens to thousands of proteins present within a single adhesion complex remains unclear. We used fluorescent molecular tension sensors to visualize force transmission by individual integrins in living cells. These measurements revealed an underlying functional modularity in which integrin class controlled adhesion size and ECM ligand specificity, while the number and type of connections between integrins and F-actin determined the force per individual integrin. In addition, we found that most integrins existed in a state of near-mechanical equilibrium, a result not predicted by existing models of cytoskeletal force transduction. A revised model that includes reversible cross-links within the F-actin network can account for this result and suggests one means by which cellular mechanical homeostasis can arise at the molecular level.

Integrins are heterodimeric transmembrane proteins that form the core of micrometer-sized protein assemblies, here referred to generically as focal adhesions (FAs). These structures link the cytoskeleton to the extracellular matrix (ECM) and hence play a central role in the construction of multicellular tissues (13). Proteomics studies demonstrate that ~60 proteins constitute the core integrin adhesion machinery and that >2400 proteins are potential members of the integrin adhesome (4). Previous studies have uncovered a dense web of interactions between FA proteins (5), the complexity of which poses a challenge in understanding how FAs function as an integrated whole.

In this study, we sought to better understand how FA-mediated force transmission arises at the molecular level. The rationale in doing so is that the transmission of forces between the cytoskeleton and ECM constitutes a core function of FAs and is required both for tissue morphogenesis and many forms of cell migration. Force transmission is commonly described in terms of the molecular clutch model, in which continuous slippage between the rearward-flowing actin cytoskeleton and FA components mediates force transmission to the ECM (610). This model reproduces important biological observations, for example biphasic traction forces as a function of substrate stiffness (1113). However, to our knowledge, the clutch model has not been directly tested by the observation of the dynamics of force transmission at the single-molecule level in living cells.

We used fluorescence resonance energy transfer (FRET)based molecular tension sensors (MTSs) to measure the loads experienced by individual integrin heterodimers in human foreskin fibroblasts (HFFs) (Fig. 1, A to D). MTSlow and MTSFN910 report on loads between 2 and 7 pN and present either a linear arginine-glycine-aspartate (RGD) containing peptide or the fibronectin type III domains 9 and 10, respectively (14, 15). In addition, we developed a new sensor termed MTShigh that measures forces between 7 and 11 pN and contains the same RGD motif as MTSlow (fig. S1) (16). We found that HFFs had similar morphology, adhesion formation, and myosin activity when adhering to surfaces functionalized with either MTSlow or MTShigh (fig. S2).

(A) FRET-based MTSs. MTSs are attached to the coverslip surface via the HaloTag domain. (B) FRET-force calibration curves for MTSlow (blue) and MTShigh (purple) (16, 51). (C) Representative images showing green fluorescent protein (eGFP) (left), FRET donor (middle), and acceptor channels (right) for HFFs adhering to a surface functionalized with MTSlow. Scale bar, 5 m; inset scale bar, 2 m. (D) Example intensity traces (left) for the FRET donor (green) and acceptor (orange). Vertical dashed lines delineate frames during which the acceptor dye was directly excited with 633-nm light; arrows mark acceptor or donor bleaching; horizontal gray dashed lines indicate upper and lower force measurement limits. Right: Corresponding load time series before acceptor photobleaching (light blue). Intensity, arbitrary units (a.u.). (E) Single-molecule load distributions for MTShigh underneath cells, within adhesions, and outside adhesions. N = number of cells, n = number of sensors. (F) Combined single-molecule load distributions for MTSlow and MTShigh sensors underneath cells, within adhesions, and outside adhesions for MTSlow [blue; data from (14)] and MTShigh (purple).

In previous studies, we found that most ligand-bound integrins exist in a minimally tensioned state (<2 pN) that does not depend on the actin cytoskeleton (14), which we confirm in this study (Fig. 1E). Measurements using MTShigh further revealed that the distribution of loads on individual integrins was highly asymmetric, with a small minority of integrins within the adhesions of HFFs bearing loads of ~6 pN and >11 (Fig. 1, E and F). The presence of the latter subpopulation is consistent with previous studies demonstrating that at least some integrins experience peak loads >50 pN (1721).

How these different load subpopulations arise at the molecular level was unclear. A plausible explanation was that these subpopulations might correspond to ligation by different integrin heterodimers, a scenario supported by studies reporting distinct roles for 51- and v-class integrins in adhesion and traction generation (2225). To test this hypothesis, we made use of pan-integrin knockout (pKO) mouse kidney fibroblasts rescued with the integrin v subunit (pKO-v), which forms predominantly v3 and v5 heterodimers, the 1 subunit (pKO-1), which forms only 51 integrin in these cells, or both subunits (pKO-v/1), which form all three integrin heterodimers (22). pKO-v and pKO-v/1 cells spread normally on coverslips functionalized with either MTSlow or MTShigh and formed sizeable FAs (Fig. 2A, top and middle), while most of the pKO-1 cells failed to spread on either sensor (see insets). In contrast, all three cell types spread on coverslips functionalized with MTSFN910. However, pKO-v cells yielded lower integrated traction forces, without significant changes in adhesion size, compared to the other two cell types [Fig. 2, A (bottom), B, and D]. Thus, integrin usage and ligand identity strongly influenced adhesion and traction generation at the whole-cell level, an outcome consistent with previous observations (14, 24, 26, 27).

(A) Images of eGFP-paxillin and ensemble FRET maps for pKO-v, pKO-v/1, and pKO-1 cells adhering to MTSlow (top), MTShigh (middle), and MTSFN910 (bottom). Insets show corresponding bright-field images for pKO-1 cells, which rarely spread on surfaces functionalized with MTSlow and MTShigh. Scale bars, 10 m. (B) Ensemble quantification of pKO-v, pKO-v/1, and pKO-1 cells adhering to MTSlow, MTShigh, and MTSFN910. When adhering to MTSlow, pKO-v/1 cells exert more integrated traction compared to pKO-v cells (pKO-v: 67 cells, mean: 5.5 nN; pKO-v/1: 43 cells, mean: 9.8 nN) (***P = 3 104). When adhering to MTShigh, pKO-v/1 and pKO-v cells produce comparable traction overall (pKO-v: 77 cells, mean: 2.6 nN; pKO-v/1: 22 cells, mean: 7 nN). For MTSFN910, pKO-v/1 and pKO-1 cells exert a higher integrated traction as compared to pKO-v cells (pKO-v: 13 cells, mean: 7.9 nN; pKO-v/1: 12 cells, mean: 26.9 nN; pKO-v/1: 12 cells, mean: 23.8 nN) (***P < 10 to 3). (C) Single-molecule load distributions for pKO cell lines adhering to MTSFN910. Black bars indicate unbound molecules. (D) Adhesion area measured for pKO-v, pKO-v/1, and pKO-1 cells adhering to MTSFN910. Areas were calculated from the thresholded eGFP-paxillin signal. Differences in adhesion area were not significant between the three cell types.

We next measured the distribution of loads experienced by individual integrins for pKO-v, pKO-1, and pKO-v/1 cells adhering to coverslips functionalized with MTSFN910. Contrary to expectation, the distributions of loads for integrins bearing >2 pN were notably similar across all three cell lines (Fig. 2B and fig. S3). However, the fraction of integrin-bound sensors underneath cells was significantly higher for pKO-v/1 and pKO-1 cells as compared to pKO-v cells (Fig. 2C and table S1), a factor that can largely account for the differences in traction generation at the whole-cell level. Thus, integrin usage indirectly influenced overall cellular traction by modulating the fraction of engaged integrins but did not influence the distribution of loads borne by individual, ligand-bound integrins.

An alternate hypothesis was that the load experienced by an integrin, regardless of class, is determined by the nature of its linkages to the actin cytoskeleton. The cytosolic protein vinculin reinforces the talin-actin linkage and may influence the load borne by individual integrins. We quantified traction generation at the whole-cell and single-integrin level for wild-type (WT) and vinculin-null (vin/) mouse embryonic fibroblasts (MEFs) adhering to MTSlow and MTShigh (Fig. 3, A and B) (28). WT but not vin/ MEFs generated appreciable regions with low FRET when adhering to MTShigh (Fig. 3B), indicating that vinculin was required for the subpopulation of integrins transmitting loads >7 pN (Fig. 3C). This observation was likewise borne out by the distribution of loads on single integrins (Fig. 3D). Thus, linkages to F-actin, but not integrin heterodimer type, helped to determine the loads transmitted by individual integrins.

(A) Ensemble FRET maps for WT and vin/ MEFs transfected with eGFP-paxillin and seeded on coverslips functionalized with MTSlow and MTShigh sensors. Scale bar, 10 m. (B) Total integrated traction per cell for forces <7 pN measured with MTSlow. Open circles indicate the mean value. (WT: 96 cells, mean: 3.6 nN; vin/: 89 cells, mean: 4.4 nN.) (C) Total integrated traction per cell for forces between 7 and 11 pN measured with MTShigh. Open circles indicate the mean. (WT: 71 cells, mean: 8.7 nN; vin/: 99 cells, mean: 1.5 nN.) (D) Histograms of the single-molecule load measurements for WT and vin/ MEFs measured for cells adhering to MTSlow for sensors outside adhesions (left) and within adhesions (right). ***P < 0.001 using two-sided Wilcoxon rank sum test.

We next examined the dynamics of force transmission at individual MTSs (Fig. 4). A large subpopulation of MTSlow and MTSFN910 yielded close-to-constant FRET levels corresponding to measurable loads <2 pN (Figs. 1D and 4). As noted above, we attribute this subpopulation to integrins that experience low loads that are independent of the cytoskeleton, for example, due to glycocalyx compression (29). In addition, we observed MTSlow, MTSFN910, and MTShigh sensor molecules that experienced loads consistent with cytoskeletally generated forces (>2 pN for MTSlow and MTSFN910; >7pN for MTShigh). Of these, most remained bound for up to tens of seconds at a close-to-constant force (Figs. 1D and 4B and table S2). This observation is in apparent contradiction with previous formulations of the clutch model, which predict continuous load-and-fail dynamics stemming from the progressive loading and failing of connections to F-actin (fig. S5). A minority of MTS FRET traces did exhibit anticorrelated changes in FRET donor and acceptor intensities indicative of dynamic changes in load (table S3 and figs. S6 to S8). We have classified these as either step (close to instantaneous at our time resolution of ~1 s) or more gradual ramp transitions (Fig. 4, A and C, and table S4). Although the clutch model predicts ramp increases and step decreases in load, it does not predict the step increases or ramp decreases in load that we observed (figs. S6 to S8). Although we cannot exclude the possibility that a subset of these events may be due to dye blinking, we rarely observe these events in our no-load control measurements (table S5). Measurements in U2OS osteosarcoma cells, which have been extensively used in studies of cell migration (30), did not show step or ramp transitions (fig. S9). Thus, dynamic changes in load, at least as assayed here, were evidently dispensable for cell adhesion.

(A) Representative traces showing step (left) and gradual ramp (right) load transitions (FRET donor: green; FRET acceptor: orange; load: blue) for HFFs adhering MTSlow. Black arrows mark acceptor or donor bleaching; dashed black lines indicate direct excitation of the FRET acceptor. Horizontal gray dashed lines indicate upper and lower force measurement limits for MTSlow. (B) Percentage low force (defined as <2 for MTSlow or < 7 pN for MTShigh) (blue), higher force but static (green), and dynamic (hashed; subset of loaded integrins) sensors for a variety of cell types adhering to different MTSs. (C) Percent of dynamic sensors with step (magenta) and ramp (purple) transitions. U2OS cells had no observable dynamic events.

Our observations prompted us to explore extensions of the clutch model that incorporated known aspects of the architecture of FAs and the actin cytoskeleton. In established versions of the clutch model, all the F-actin filaments move with the same instantaneous velocity, which scales inversely with the total tension summed over all clutches (12). Individual clutches undergo repeated cycles of loading and failure as the monolithic F-actin moves rearward (fig. S5). We explored multiple extended models that included multiple clutch-actin connections, akin to multiple vinculins linking talin to actin, viscous relaxation of the clutch, catch bond behavior, or reversible actin cross-linkers (see Model Comparisons in the Supplementary Materials and Fig. 5). Among the models examined, only the addition of reversible cross-links between actin filaments (e.g., by -actinin, filamin, nonmuscle myosin II, or other cross-linkers), yielded long periods of close-to-constant loads analogous to those observed in single-molecule measurements (Fig. 5, A to C). This result reflected the establishment of temporary mechanical equilibria between discrete clusters of motors (e.g., nonmuscle myosin II) and clutches (talin and vinculin). In addition, simulations recapitulated occasional step transitions, which reflected the disconnection or reattachment of an individual clutch to an actin filament, and ramp transitions, whose time scale reflected the equilibration of loads within the cross-linker network.

(A) Simplified cartoon of a FA: Nonmuscle myosin II pulls on reversibly cross-linked actin filaments, which are linked to integrins by vinculin and talin. (B) Cytoskeletal dynamics model: F-actin filaments bind to anchors (blue) and are linked by cross-linking proteins (green). (C) An example force trace of the standard clutch model and possible clutch model extensions that account for multivalent clutch connections, viscous relaxation, or reversible cross-links. Reversible cross-links allow for stable force plateaus as well as sporadic ramp and step events. The dashed gray lines indicate zero force. (D) Calculated energy dissipation from simulations with irreversible (top) and reversible (bottom) cross-links. (E) Force distribution for simulated anchors with reversible cross-linking (kx,off = 20 s1).

Besides the addition of cross-linker binding and release rates [based on those of -actinin (31)], the model required only minor tuning compared to a previously published clutch model (8). In contrast, irreversible cross-links between F-actin, as well as other clutch model extensions, resulted in load-and-fail dynamics, analogous to previous clutch models (Fig. 5C). These load-and-fail cycles are predicted to be costly in terms of energy dissipated in the repeated stretching of individual anchor linkages: In line with this understanding, models featuring reversible cross-linker dynamics predicted lower energy dissipation for similar overall force levels (Fig. 5D). Simulations performed with low substrate stiffnesses produced similar load dynamics (fig. S10). This result reflects the use of a clutch rupture force (Fb; table S6) that is larger than the typical load borne by an individual clutch linkage, a choice in parameterization that was necessary to reproduce the long-lived binding events that we observe (Figs. 1 and 4). It is possible that the dynamics and force sensitivity of the clutch connection to F-actin may differ in different cell types, and possibly in different compartments of the cell, for example, in nascent adhesions versus stable FAs.

The above model describes the loads borne by individual linkages to F-actin rather than by the integrins themselves. However, the anchor force distributions for simulations with reversible cross-linkers qualitatively match the observation of a peak in the measured load distributions for MTSlow and MTShigh (Figs. 5E and 1, E and F). Talin contains three actin binding sites and can recruit up to 11 vinculin molecules (32, 33). It is plausible that these connections to F-actin act in parallel, resulting in a broad range of loads transmitted by individual integrins. This possibility is supported by our observation of distinct subpopulations of integrins bearing ~6 and >11 pN within the FAs of HFFs (Fig. 1F), potentially reflecting multiple connections to F-actin. Single-pN loads are broadly consistent with a report that the average load experienced by talin was <6 pN (34). However, previous reports also describe >11-pN loads for a subset of talin molecules (35) and peak loads of >50 pN for a subset of integrins (21); these higher loads likely reflect additional, vinculin-mediated connections to F-actin (Fig. 3, A and C). In total, these observations are consistent with the hypothesis that the addition of multiple linkages to F-actin can result in a wide range of loads on individual integrins.

Actin retrograde flow rates provide an independent means of testing cytoskeletal clutch models (8, 12, 24). To examine how the simulated actin velocities compared with our system, we measured the velocity of F-actin filaments by treating living HFFs with 50 nM SiR-actin, a fluorogenic small-molecule probe that binds to F-actin. The mean speed for F-actin within both adhesions and linear F-actinrich structures (e.g., stress fibers) was 7.9 nm/s (95% confidence interval: 7.6-8.1 nm/s; 9 cells, 2355 tracks), comparable to the mean velocity of 5 nm/s observed in reversible cross-linker simulations. These measured and simulated velocities are approximately one-half to one-third the magnitude of F-actin speeds measured in the lamellipodia of Xenopus XTC cells, respectively, differences that may reflect a decrease in F-actin velocities near adhesions (36).

Previously, we found that most of the integrins exist in a minimally tensioned state (14). Here, we extend this result and report that a small fraction of ligand-engaged integrins support loads >11 pN. The large majority of integrins thus experience loads substantially less than their maximum capacity. This mechanical reserve may allow cells to withstand external stresses that would threaten tissue integrity. Conversely, the ability to exert large, localized forces via a few integrins may be essential for cell migration and mechanosensing, for example, in fibrous ECM networks, where local effective stiffnesses can span several orders of magnitude (37, 38). Integrin complexes thus represent an interesting example of how a highly asymmetric distribution of activity at the molecular level (here, force transmission) can yield flexible and robust functionality at the cell and tissue levels.

Contrary to expectation, most of the integrins experienced close-to-constant loads within the resolution of our measurements (10). Although several nonexclusive factors, for example, domain unfolding in talin (33), may contribute to this observation, a model that incorporates reversible cross-links in the F-actin cytoskeleton is sufficient to account for our observations. This model is consistent with reports demonstrating that -actinin cross-linking activity can change the mechanical properties of F-actin networks (39) and influence cell migration and traction force generation (40), although multiple actin cross-linkers are likely to contribute. Force transmission through a network of dynamic cross-linkers also reduced energy consumption compared to a system that underwent repeated load-and-fail cycles (Fig. 5D). We suggest that, despite the complexity of adhesion complexes, cellular mechanical homeostasis and efficient force transmission may arise from the core dynamical properties of the cytoskeleton. Additional tests in other model systems will, however, be required to establish the generality of this supposition.

Our data imply that the chain of molecular linkages between individual tension sensors and F-actin can remain stable for tens of seconds even under appreciable loads (Figs. 1 and 4 and table S2). This observation, in turn, suggests that the load on individual clutch linkages is, on average, appreciably less than their characteristic Fb (table S6). In the modified clutch model, this parameterization predicts adhesions whose stability is relatively insensitive to substrate stiffness (fig. S10). In contrast, adhesions with smaller Fb, or equivalently a higher average load per clutch, are predicted to yield load-and-fail dynamics at individual clutches and sensitivity to substrate stiffness as predicted in the original clutch model (8, 12). Determining whether the force sensitivity of adhesions differs as a function of cell type, matrix properties, and/or adhesion maturation provides an important target for future work. We speculate that modulation of key parameters such as the average load per clutch may provide a potent yet flexible method for cells to change mechanical states in response to external stimuli.

A core result of systems biology is that cellular subsystems, for example, signal transduction pathways, are often organized into semiautonomous functional modules, an outcome thought to enhance both robustness and evolvability (41, 42). Although previously proposed (5), whether a similar functional modularity might apply to complex structural assemblies such as FAs has been unclear. Our observations suggest that, despite a dense web of protein-protein interactions (43), FAs maintain modularity at a functional level. In the model systems studied here, the force-transducing machinery linking F-actin to adhesions resulted in per-integrin load distributions that were essentially identical regardless of integrin heterodimer usage (Fig. 2C). Integrin heterodimer usage in turn determined both ligand specificity and adhesion stability and, hence, influenced cellular adhesion and traction output. The flexibility afforded by this modular organization is likely to have greatly facilitated the evolution of the remarkable functional diversity of integrin-based adhesion complexes in metazoans.

Our findings complement work demonstrating that some proteins are recruited to FAs as part of preassembled complexes (4446), suggestive of a hierarchical assembly process. These preassembled protein complexes are, however, not necessarily synonymous with single, defined functions; in other systems, evolutionary data demonstrate that biological function is often preserved even when the protein(s) fulfilling that function are not (47). Compositional and functional modularity may thus constitute distinct, and complementary, principles that govern the form and function of complex macromolecular assemblies.

MTSlow and MTSFN910 were prepared as previously described (14, 15). The high-force MTS (MTShigh) was adapted from MTSlow by replacing the (GPGGA)8 module with another tension-sensitive domain, termed HPst (LSDED FKAVF GMTRS AFANL PLWKQ QALMK EKGLF), derived from the villin headpiece (16). The DNA encoding this construct was assembled by Epoch Life Sciences Inc. (Missouri City, TX) and was cloned into the pJ414 expression vector (DNA 2.0). We used Alexa 546 maleimide (Thermo Fisher Scientific, A10258) as the FRET donor and an Alexa 647 maleimide dye (Thermo Fisher Scientific, A20347) as the FRET acceptor. This modified MTS presents the identical RGD ligand derived from fibronectin as used in MTSlow. The entire MTShigh sequence is presented below:

M G S E I G T G F P F D P H Y V E V L G E R M H Y V D V G P R D G T P V L F L H G N P T S S Y V W R N I I P H V A P T H R S I A P D L I G M G K S D K P D L G Y F F D D H V R F M D A F I E A L G L E E V V L V I H D W G S A L G F H W A K R N P E R V K G I A F M E F I R P I P T W D E W P E F A R E T F Q A F R T T D V G R K L I I D Q N V F I E G T L P M G V V R P L T E V E M D H Y R E P F L N P V D R E P L W R F P N E L P I A G E P A N I V A L V E E Y M D W L H Q S P V P K L L F W G T P G V L I P P A E A A R L A K S L P N A K A V D I G P G L N L L Q E D N P D L I G S E I A R W L S T L E I S G G A G E F K C A G L S D E D F K A V F G M T R S A F A N L P L W K Q Q A L M K E K G L F G K C A G S E N L Y F Q G T V Y A V T G R G D S P A S S A A H H H H H H.

Sensors were expressed in BL21(DE3) competent Escherichia coli. Cultures (500 ml) were grown overnight at 30C with ampicillin (100 g/ml) and induced with 1 mM isopropyl--d-thiogalactopyranoside at an optical density of 0.6. The bacteria were then spun down at 6000g for 30 min and resuspended in 10 ml of lysis buffer [50 mM sodium phosphate, 300 mM NaCl, and 10 mM imidazole, (pH 8)] with a protease inhibitor cocktail (11873580001, Roche) and 10 M lysozyme. The resuspended cells were rocked for 30 min at 4C, lysed with a tip sonicator, and spun at 14,000g for 30 min. The supernatant was incubated with 2 ml of nickelnitrilotriacetic acid HisPur Resin (Thermo Fisher Scientific) and rocked at 4C for 2 hours. The solution was then packed into a gravity column, washed three times with 5 ml of wash buffer [50 mM sodium phosphate, 300 mM NaCl, and 20 mM imidazole (pH 7.4)], and incubated with 4 ml of elution buffer [50 mM sodium phosphate, 300 mM sodium chloride, and 250 mM imidazole (pH 7.4)] for 5 min. The eluate was collected and dialyzed overnight into storage buffer [1 phosphate-buffered saline (PBS), 1 mM EDTA, and 2 mM -mercaptoethanol], flash-frozen, and stored at 80C. Fractions were characterized by SDSpolyacrylamide gel electrophoresis (SDS-PAGE), and the concentration was determined by ultravioletvisible (UV-Vis) spectroscopy (fig. S1).

Labeling of MTSs was performed through dual cysteine labeling and subsequent purification to separate the population of sensors with a single donor and acceptor dye. The cysteines were first reduced with 2 mM tris(2-carboxyethyl)phosphine for 30 min at room temperature and buffer exchanged into labeling buffer [50 mM phosphate buffer, 150 mM NaCl, and 1 mM EDTA (pH 7.4)] using three 7K Zeba desalting columns (89883, Thermo Fisher Scientific) in series. Alexa 546 and Alexa 647 maleimide dyes were added at a protein:donor:acceptor ratio of 1:1.5:2 for 1 hour at room temperature and overnight at 4C. To help remove free dye and exchange the protein into fast protein liquid chromatography (FPLC) buffer A [50 mM tris buffer (pH 8) and 5 mM -mercaptoethanol], the solution was passed through two PD MiniTrap desalting columns (45001529, GE Healthcare) in series. To separate out the sensors with a single donor and single acceptor, we used an AKTA Pure FPLC (GE Healthcare) with a MonoQ PC 1.6/5 (GE Healthcare) ion exchange column and a 10 mM/ml linear salt gradient with buffer B [50 mM tris (pH 8), 5 mM -mercaptoethanol, and 2 M NaCl]. Fractions were characterized using SDS-PAGE, UV-Vis spectroscopy, and single-molecule imaging. The desired fractions were concentrated and exchanged into PBS using 3K centrifugal filters (Amicon) and stored at 80C.

Coverslips were prepared as previously described (14). Briefly, 24 mm by 50 mm no. 1 coverslips (Fisherbrand) were sonicated in a bath sonicator (Kendall) for 20 min with isopropanol, Milli-Q water, and 5 M KOH, with Milli-Q water rinses between each step. The coverslips were then sonicated for 5 min in methanol and transferred to a solution of 2-ml N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (97%) (A0700, UCT Specialties), 10-ml glacial acetic acid, and 200-ml methanol. The coverslips were incubated in the silane mixture for 10 min, sonicated for 1 min, and then incubated for another 10 min. They were then rinsed with Milli-Q water and dried with nitrogen. To passivate the coverslips, 100 mg of maleimide polyethylene glycol (PEG) succinimidyl carboxymethyl ester (molecular weight, 5000; A5003-1, JenKem Technology) was dissolved in 1 ml of 100 mM phosphate buffer (pH 7.0). Two coverslips were sandwiched with 100 l of the PEG solution in between for 1 hour at room temperature and protected from light. The coverslips were then washed with Milli-Q water and dried before being incubated overnight with 100 l of 3 mM Halo ligand thiol (P6761 Promega or AcmeBiosciences Inc.) in 100 mM phosphate buffer (pH 7.0). Afterward, the coverslips were washed with Milli-Q water, dried, and stored in vacuum-sealed bags at 20C.

Flow chambers were attached to PEGylated coverslips as previously described (15). For ensemble experiments, chambers were prepared with 100 nM double-labeled sensor and incubated at room temperature for 30 min. For the single-molecule assay, 100 nM unlabeled sensor with 100 pM labeled sensor was mixed in PBS and added to the flow cells for 30 min. The chambers were then washed with 200 l of PBS and Pluronic F-127 (0.2% w/v) for ~1 min to prevent nonspecific cell attachment. The chambers were washed again with PBS to remove excess Pluronic. Cells were then added and incubated for at least 1 hour at 37C in Dulbeccos modified Eagles medium (DMEM) high-glucose medium. FRET measurements were made within 3 hours of plating the cells and acquired with an objective heater (Bioptechs) set to 37C. Images were prepared in Fiji (48) and analyzed using custom MATLAB scripts.

For immunofluorescence, cells were fixed with 4% paraformaldehyde for 15 min at 37C and washed with PBS. Cells were then permeabilized with 0.1% Triton X-100 in PBS for 5 min, washed with PBS, and then blocked with 5% bovine serum albumin (BSA) for 1 hour at room temperature. Antibodies for myosin IIa (Sigma-Aldrich, no. M8064; 1/100 dilution) and phosphorylated myosin light chain (Cell Signaling Technologies, no. 3675S; 1/200 dilution) were incubated with 5% BSA for 45 min at room temperature. Secondary antibodies (anti-rabbit 647, Cell Signaling Technologies, no. 4414S; and anti-mouse 555, Cell Signaling Technologies, no. 4409S; 1/200 dilution) were incubated with 5% BSA for 45 min at room temperature.

Single-molecule and ensemble FRET fluorescence measurements were performed with objective-type total internal reflection fluorescence (TIRF) microscopy on an inverted microscope (Nikon TiE) with an Apo TIRF 100 oil objective lens, numerical aperture 1.49 (Nikon) as described previously (14) and controlled using Micromanager (49). Samples were excited with 473-nm OBIS laser (Coherent), 532-nm (Crystalaser), or 635-nm (Blue Sky Research) lasers. For single-molecule data, emission for the FRET donor and emission channels were separated as previously described and recorded on an electron-multiplying charge-coupled device camera (Andor iXon) (15). For collection of the green fluorescent protein (GFP) signal, we used an additional set of emission filters mounted on a motorized flip mount (Thorlabs Inc.) placed the donor fluorescence emission path. Filters used included a 593/40 nm filter (Semrock Inc.) for the collection of donor emission, a 675/30 nm filter for the collection of acceptor emission, and a 514/30 nm filter (Semrock Inc.) for GFP emission collection. For ensemble FRET maps taken for whole cells, emitted light passed through a quad-edge laser-flat dichroic with center/bandwidths of 405/60 nm, 488/100 nm, 532/100 nm, and 635/100 nm from Semrock Inc. (Di01-R405/488/532/635-2536) and corresponding quad-pass filter with center/bandwidths of 446/37 nm, 510/20 nm, 581/70 nm, 703/88 nm band-pass filter (FF01-446/510/581/703-25). GFP, donor, and acceptor images were taken through separate additional cubes stacked into the light path (GFP: 470/40 nm, 495 nm long-pass, and 525/50 nm; donor: 550 nm long-pass; acceptor: 679/41 nm and 700/75 nm) and recorded on a Hamamatsu Orca Flash 4.0 camera.

HFF cells CCD-1070Sk (American Type Culture Collection CRL-2091) were cultured in DMEM high-glucose medium (Gibco, catalog no. 21063-029) in the absence of phenol red and supplemented with 10% fetal bovine serum (FBS; Axenia Biologix LLC ), sodium pyruvate (1 mM, Gibco), MEM nonessential amino acids (1; Gibco), and penicillin/streptomycin (100 U/ml and 100 g/ml; Gibco), herein referred to as normal culture medium. The cells were grown at 37C with 5% CO2. Fibroblasts with stably expressing eGFP-paxillin (fused at the C terminus) were prepared as previously described (15).

pKO mouse kidney fibroblasts rescued with either v, 1, or both v and 1 integrin subunits were a gift from R. Fssler (Max Planck Institute Martinsried) (22). Cells were cultured on fibronectin-coated plastic (5 g/ml; Corning, diluted in PBS and incubated at 37C for 1 hour) in normal culture medium described above. pKO-1 cells in particular were sensitive to the quality of fibronectin coating; thus, a minimum of 1 and 4 ml of the diluted fibronectin solution (5 g/ml) were used per well for a six-well and 10-cm dish, respectively. Cells were grown at 37C with 5% CO2.

WT and vin/ MEFs were a gift from K. Rothenberg and B. Hoffman (Duke University) (28). Cells were cultured on tissue culture plastic in normal culture medium at 37C and 5% CO2.

U2OS cells were a gift from M. Franklin and J. Liphardt (Stanford University). Cells were cultured on tissue culture plastic in normal culture medium at 37C and 5% CO2.

pKO-integrin cells and WT and vinculin KO MEF cells were transfected using a similar protocol to the one previously described for eGFP-paxillin human fibroblasts (15). Cells were trypsinized, pelleted, resuspended in medium lacking FBS and penicillin/streptomycin, and counted. pKO-integrin cells (2 106) and WT (5 105) and vinculin KO cells were repelleted at 800 rpm for 10 min. P4 Nucleofector solution (82 l) was added to 18 l of P4 supplement in a 1.5-ml Eppendorf tube and used to resuspend the cell pellet. DNA for C-terminal eGFP-paxillin (Addgene, no.15233) cloned into the DNA 2.0 PiggyBac vector (~4 g) was added to the cells and gently flicked before transferring to a Lonza nucleofection cuvette. Cuvettes were placed in a Lonza 4D-Nucleofector system and program C2167 (for MEFs) was used. Warm medium (500 l) was added to the cuvette, and cells were transferred to a six-well plate with medium equilibrated at 37C with 5% CO2 using a pipette bulb without pipetting up and down. Cells were selected with puromycin (1 to 2.0 g/ml) 24 hours after transfection for 4 to 6 days.

Single-molecule data were acquired and analyzed as described previously (14). Briefly, data were acquired with excitation with a 532-nm laser at 5 frames/s for 300 or 600 frames and with direct acceptor excitation at 635 nm for approximately 10 frames at roughly frame 100. The direct excitation helped to distinguish between low-FRET sensors and sensors without an acceptor dye.

Traces were analyzed using a custom MATLAB code, and donor and acceptor channels were aligned using a single-molecule high-resolution colocalization map generated by scanning across a field of beads (50). The positions of individual sensors were then detected using a spot-finding algorithm (T. Ursell, Stanford University) and were determined to be colocalized if within two pixels. Intensities were calculated on the basis of an average of 7 7 pixels centered around the detected spot and corrected for spectral bleedthrough.

Intensities for each dye were averaged over manually identified FRETing, non-FRETing, and bleached regions. When the acceptor bleached before the donor, we used the following expression to calculate FRET efficiencyE=(IaIa,back)(IaIa,back)+(IdId,back)=IaIa,backId,0Idwhere Ia is the acceptor intensity during FRET, Ia,back is the acceptor background intensity, Id is the donor intensity during FRET, Id,0 is the donor intensity after acceptor photobleaching, Id,back is the donor background intensity, and is the correction factor accounting for relative dye quantum yields and instrument detection efficiencies.

When the donor fluorophore bleached first, the FRET efficiency was calculated asE=(IaIa,back)(IaIa,back)+0(IdId,back)

Values for 0 were 0.40 for MTSlow, 0.52 for MTSFN, and 0.52 for MTShigh.

Events were double-checked by generating a series of z projections for the donor and acceptor molecule during FRETing, non-FRETing, and bleached states. The autoGaussianSurf Matlab function (P. Mineault) was used to fit a two-dimensional Gaussian to the 7 7pixel area to determine whether the spot represented a single emitting fluorophore. Low-FRET events were verified as having a functional acceptor by direct excitation with a 635-nm laser.

Combined single-molecule histograms for MTSlow and MTShigh were created by normalizing the proportion of molecules for the overlapping force bins. The proportion of molecules greater than 7 pN measured previously using MTSlow nearly matched the proportion of molecules bearing greater than 7 pN measured using MTShigh (14). The final histograms were created by scaling the force distribution measured by MTShigh by the proportion of molecules bearing greater than 7 pN measured using MTSlow for molecules within adhesions, underneath cells, and outside adhesions separately.

The FRET versus force response of the (GPGGA)8 linker used here was previously reported by Grashoff et al., and an updated calibration was recently reported by LaCroix et al. (51, 52). We used the updated MATLAB calibrations from LaCroix et al. to generate improved FRET versus force calibration curves. Using 43 amino acids (for the eight repeats of GPGGA plus the two cysteines and a single lysine), a fluorophore radius of 0.5 nm, a Forster radius of 6.95 nm, and persistence lengths from 0.87 to 0.98 nm, we constructed three FRET-force calibration curves to account for the slightly different resting FRET efficiencies determined experimentally (fig. S11).

Ensemble measurements were performed as previously described (14). In summary, images of eGFP-paxillin marked cells were acquired using a Hamamatsu Orca Flash 4.0 camera and were subsequently corrected for illumination spatial inhomogeneities, background-subtracted, and intensity-normalized. The GFP image was then boxcar-averaged (moving average v3.1 from MATLAB Central File Exchange) at 10 different rotations of the original image at 20 intervals, thresholded, and segmented using a watershed algorithm. The segmented image was then corrected to combine adjacent islands representing a single adhesion and filtered to exclude islands below a lower limit (0.5 m2). The segmented GFP image was then used to mask the corresponding FRET signal.

FRET images were converted to FRET index values by dividing the acceptor intensity over the sum of the donor and the acceptor signal. Then, the FRET images were converted to FRET efficiency after correcting to dye labeling efficiency, bleedthrough, the measured no-load FRET efficiency, and the FRET-index measured outside the cell (14). The total integrated traction of a cell was calculated by summing the force contributions (defined as the average pixel value times number of pixels) for pixels within adhesions. For MTSlow or MTSFN910, forces corresponding to >7pN were set to 7.1 pN. For MTShigh measurements, calculated forces corresponding to <7 pN were set to 0 pN.

Traces with potential dynamic behavior, identified by having distinct anticorrelated signals, were marked and analyzed individually. Step events were classified by having large anticorrelated changes in the donor and acceptor signal within the period of one to three frames (0.2 to 0.6 s) and were manually annotated. Force traces were smoothed using a median filter over five frames. Ramp events were classified by having more gradual anticorrelated changes and were manually marked. Ramp traces were then converted to the force domain, and only changes in load between 2 and 7 pN were fit. Dynamic events were only accepted if the acceptor was confirmed to be active and could not be accounted for by either donor or acceptor photobleaching. Very few dynamic-like sensors were observed under no-load conditions (table S5).

Halo-PEG coverslips were incubated with 100 nM unlabeled RGD sensor at room temperature for 30 min, and cells were seeded and allowed to spread for at least ~1 hour. After a 9-min incubation with 50 nM SiR-actin (Cytoskeleton Inc., no. CY-SC001), the sample was incubated with Prolong Live Antifade Reagent (Invitrogen, P36975) for 1 hour. The low dilution of SiR-actin allowed for individual molecules to be tracked, and the addition of Prolong reduced photobleaching. For each cell, a 100-ms exposure of the GFP-paxillin channel (for masking) was first acquired, followed by a 60-frame sequence in the far red channel (SiR-actin) with 300-ms exposures taken every 2 s.

For fixed cell control data, cells were allowed to spread on functionalized coverslips and then fixed in 4% paraformaldehyde for 15 min at room temperature. After rinsing, the cells were treated with SiR-actin and Prolong reagent as above.

Speckles and tracks were identified using quantitative fluorescent speckle microscopy software made available by the Danuser laboratory (53). The localizations, which are given with pixel precision, are fit to subpixel positions by Gaussian fitting.

Every frame was used to track speckles, but velocities were calculated from speckle displacements over five frames (10 s), giving velocities on the time scale of our FRET measurements. Adhesions were masked by an Otsu threshold of the eGFP-paxillin image after background subtraction to remove the diffuse cytoplasmic signal. F-actin stress fibers were masked as the brightest 3% of pixels of a time-series projection of the F-actin tracks. We measure the actin velocities of tracks that originate both over stress fibers and adhesions.

From our mean velocity measurement, , we calculate a corrected velocity, s, using the following relation (50)s=d242where is the localization error (SD) of single-molecule localizations (estimated to be 47 nm here).

In the reversible cross-linker model, F-actin was treated as a network of filaments connected by noncompliant dynamic cross-linkers (Fig. 4). These cross-linkers bind and unbind at rates kx,on and kx,off. Each clutch is bound to an individual filament, and the number of motors per filament is dictated by simulation parameters (table S6). Force traces were averaged over 1-s time steps to reflect the time scale of the processed force traces from the single-molecule measurement. Individual clutches experience load routed from different combinations of motors at any given instant, where individual loads are dictated by both the force-velocity relationships of individual motors and the loading history of the clutches within the cluster. The forces on individual clutches build until the F-actin retrograde flow rate is close to 0 and the motor stall force and clutch force are nearly equal. When a cross-linker binds or unbinds, the forces on the associated clutches are no longer balanced, and the F-actin velocities adjust to reestablish mechanical equilibrium.

In the resulting simulations, dynamic clusters of clutches continuously stretch and relax, oscillating around force plateaus for periods of 10 to 60 s. Ramp and step transitions are observed throughout these simulations, in a manner consistent with our experimental observation: A step transition occurs when a binding clutch quickly builds force or when an unbinding clutch instantaneously returns to 0 force. More gradual ramp transitions occur in neighboring clutches as the associated loads readjust to achieve a force balance within the cluster.

Although a variety of models were explored, the dynamic F-actin network best captured the behavior observed experimentally. In contrast to the other models, the force plateaus persisted the longest with minimal fluctuations, and the single-clutch dynamics were consistent across simulation parameters (i.e., relatively insensitive to small parameter changes). Although further testing of the dynamic F-actin network model is still needed and alternate models have not been definitively ruled out, the dynamic F-actin model best captures the experimentally observed behavior of the individual sensor force distribution and force dynamics.

Energy dissipation was calculated as the sum of stored energy in anchors upon unbinding. When an unbinding event occurred, the stored energy in the anchor was calculated using the spring constant of the anchor and its displacementE=12kcx2

The running sum of this value was recorded for the duration of the experiment. This does not account for energy dissipation within the motor-actin system.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: We thank K. Rothenberg of the Hoffman laboratory (Duke University) for the vin/ MEFs, M. Franklin from the Liphardt laboratory (Stanford University) for the U2OS cells, and R. Fssler (Max Planck Institute, Martinsried) for the pKO cells. We thank the Khosla laboratory for their protein purification expertise and access to their equipment. We would also like to thank A. LaCroix from the Hoffman laboratory (Duke University) for useful discussions on FRET-force calibrations and B. Zhong, E. Korkmazhan, C. Garzon-Coral, W. Weis, and O. Chaudhuri for useful discussions and feedback. The data reported in this paper are further detailed in the Supplementary Materials. Funding: Research reported in this publication was supported by grants R01-CA172986 and U54-CA210190 to D.J.O. and R01-GM112998-01 and R35-GM130332 to A.R.D. from the National Institutes of Health (NIH). The research of A.R.D. was supported, in part, by a Faculty Scholar from the Howard Hughes Medical Institute. S.J.T. was supported by the John Stauffer Stanford Graduate Fellowship from Stanford, and A.C.C., C.M.M., and L.S.P. were supported by Graduate Research Fellowships from the National Science Foundation (00039202). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Author contributions: S.J.T., A.C.C., and C.M.M. performed experiments and analyzed data. S.M.A., L.S.P., and A.R.D. created and ran clutch model simulations. All authors contributed to the writing and editing of the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Originally posted here:
Regulation and dynamics of force transmission at individual cell-matrix adhesion bonds - Science Advances

Cloud Computing in Cell Biology, Genomics and Drug Development Market Analysis by Top Key Players, Considering Growth and Demand with Product Type,…

The Cloud Computing in Cell Biology, Genomics and Drug Development Market report market intelligence study intended to offer complete understanding of global market scenario with the Impact of COVID-19 (Corona Virus). It attempts to analyze the major components of the Market which have greater influence on it. This includes various elements of significant nature including market overview, segmentation, competition landscape, Market chain analysis, key players strategyand more. Also, the report provides a 360-degree overview of global market on the basis of various analysis techniques including SWOT and Porters Five Forces. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. This might help readers to understand the strengths, opportunities, challenges and perceived threats of the market.

The following Companies are coveredin theResearch Report: Amazon Web Services (AWS) Inc., Cisco Systems Inc., DXC Technology, Google LLC, Salesforce.com Inc., and SAP SE

Based on Classification, each type is studied as Sales, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. The report can help to realize the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Cloud Computing in Cell Biology, Genomics and Drug Development industry.

The Cloud Computing in Cell Biology, Genomics and Drug Development Market report wraps:

There are 13 Chapters to thoroughly display the Cloud Computing in Cell Biology, Genomics and Drug Development market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

In the end, The objective of the market research report is the current status of the market and in accordance classifies it into a few objects. The report takes into consideration the first market players in every area from over the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Here is the original post:
Cloud Computing in Cell Biology, Genomics and Drug Development Market Analysis by Top Key Players, Considering Growth and Demand with Product Type,...

Immunai wants to map the entire immune system and raised $20 million in seed funding to do it – TechCrunch

For the past two years the founding team of Immunai had been working stealthily to develop a new technology to map the immune system of any patient.

Founded by Noam Solomon, a Harvard and MIT-educated postdoctoral researcher, and former Palantir engineer, Luis Voloch, Immunai was born from the two mens interest in computational biology and systems engineering. When the two were introduced to Ansuman Satpathy, a professor of cancer immunology at Stanford University, and Danny Wells, who works as a data scientist at the Parker Institute for Cancer Immunotherapy, the path forward for the company became clear.

Together we said we bring the understanding of all the technology and machine learning that needs to be brought into the work and Ansu and Danny bring the single-cell biology, said Solomon.

Now as the company unveils itself and the $20 million in financing it has received from investors including Viola Ventures and TLV Partners, its going to be making a hiring push and expanding its already robust research and development activities.

Immunai already boasts clinical partnerships with over ten medical centers and commercial partnerships with several biopharma companies, according to the company. And the team has already published peer-reviewed work on the origin of tumor-fighting T cells following PD-1 blockade, Immunai said.

We are implementing a complicated engineering pipeline. We wanted to scale to hundreds of patients and thousands of samples, said Wells. Right now, in the world of cancer therapy, there are new drugs coming on the market that are called checkpoint inhibitors. [Were] trying to understand how these molecules are working and find new combinations and new targets. We need to see the immune system in full granularity.

Thats what Immunais combination of hardware and software allows researchers to do, said Wells. Its a vertically integrated platform for single cell profiling, he said. We go even further to figure out what the biology is there and figure that out in a new combination design for the trial.

Cell therapies and cancer immunotherapies are changing the practice of medicine and offering new treatments for conditions, but given how complex the immune system is, the developers of those therapies have few insights into how their treatments will affect the immune system. Given the diversity of individual patients, variations in products can significantly change the way a patient will respond to the treatment, the company said.

Photo: Andrew Brookes/Getty Images

Immunai has the potential to change the way these treatments are developed by using single-cell technologies to profile cells by generating over a terabyte of data from an individual blood sample. The companys proprietary database and machine learnings tools map incoming data to different cell types and create profiles of immune responses based on differentiated elements. Finally, the database of immune profiles supports the discovery of biomarkers that can then be monitored for potential changes.

Our mission is to map the immune system with neural networks and transfer learning techniques informed by deep immunology knowledge, said Voloch, in a statement. We developed the tools and know-how to help every immuno-oncology and cell therapy researcher excel at their job. This helps increase the speed in which drugs are developed and brought to market by elucidating their mechanisms of action and resistance.

Pharmaceutical companies are already aware of the transformational potential of the technology, according to Solomon. The company is already in the process of finalizing a seven-figure contract from a Fortune 100 company, according to Solomon.

One of the companys earliest research coups was using research to show the way that immune systems function when anti-PD1 molecules are introduced. Typically the presence of PD-1 means that T cell production is being suppressed. What the research from Immunai revealed was that the response wasnt happening with T cells within the tumor. There were new T cells that were migrating to the tumor to fight it off, according to Wells.

This whole approach that we have around looking at all of these indications we believe that the right way and most powerful way to study these diseases is to look at the immune system from the top down, said Voloch, in an interview. Looking at all of these different scenarios. From the top, you see these patterns than wouldnt be available otherwise.

See original here:
Immunai wants to map the entire immune system and raised $20 million in seed funding to do it - TechCrunch

New research into stem cell mutations could improve regenerative medicine – Express Healthcare

The new research has suggested ways to reduce the likelihood of mutations occurring in these cells when cultured

Research from the University of Sheffield has given new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring.

The findings, publishedin Stem Cell Reports, show that pluripotent stem cells are particularly susceptible to DNA damage and mutations compared to other cells, and this could cause genetic mutations.Pluripotent stem cells are able to develop into any cell type in the body, and there is considerable interest in using them to produce cells to replace diseased or damaged tissues in applications referred to as regenerative medicine.

One concern for the safety of this is that these cells often acquire recurrent mutations which might lead to safety issues if used in patients.The researchers have found that these mutations are more likely to occur in a certain point during their cell cycle and have suggested ways of growing the cells to dramatically reduce the susceptibility to DNA damage and potentially the mutations that arise.

Peter Andrews, Professor of Biomedical Science at the University of Sheffield, informed,Clinical trials of regenerative medicine using cells derived from pluripotent stem cells are now beginning around the world, but there are concerns that mutations in the pluripotent stem cells may risk patient safety. Our results may allow us to significantly reduce that risk.Understanding the genetic stability of human pluripotent stem cells is an area developed at the University of Sheffield and one in which we are an international leader.The Department of Biomedical Science at the University of Sheffield carries out world-leading research to understand the disease, improve treatments, and find potential cures. Researchers work in areas ranging from cell biology and developmental biology to neuroscience and regenerative medicine, with expertise in topics including stem cells and cancer.

View post:
New research into stem cell mutations could improve regenerative medicine - Express Healthcare

Cell Pores Discovery Offers New Hope for Millions With Brain and Spinal Cord Injuries – SciTechDaily

New research from a team of international scientists shows how swelling associated with brain and spinal cord injury can be stopped using a drug already licensed for human use.

Scientists have discovered a new treatment to dramatically reduce swelling after brain and spinal cord injuries, offering hope to 75 million victims worldwide each year.

The breakthrough in treating such injuries referred to as central nervous system (CNS) edema is thought to be hugely significant because current options are limited to putting patients in an induced coma or performing risky surgery.

Brain and spinal cord injuries affect all age groups. Older people are more at risk of sustaining them from strokes or falls, while for younger age groups, major causes include road traffic accidents and injuries from sports such as rugby, US-style football and other contact games.

The high-profile example of Formula 1 racing driver Michael Schumacher demonstrates the difficulties physicians currently face in treating such injuries. After falling and hitting his head on a rock while skiing in Switzerland in 2013, Schumacher developed a swelling on his brain from water rushing into the affected cells. He spent six months in a medically-induced coma and underwent complex surgery, but his rehabilitation continues to this day.

The new treatment, developed by an international team of scientists working at Aston University (UK), Harvard Medical School (US), University of Birmingham (UK), University of Calgary (Canada), Lund University (Sweden), Copenhagen University (Denmark) and University of Wolverhampton (UK), features in the latest edition of the scientific journalCell.

The researchers used an already-licensed anti-psychotic medicine trifluoperazine (TFP) to alter the behavior of tiny water channel pores in cells known as aquaporins.

Testing the treatment on injured rats, they found those animals given a single dose of the drug at the trauma site recovered full movement and sensitivity in as little as two weeks, compared to an untreated group that continued to show motor and sensory impairment beyond six weeks after the injury.

The treatment works by counteracting the cells normal reaction to a loss of oxygen in the CNS the brain and spinal cord caused by trauma. Under such conditions, cells quickly become saltier because of a build-up of ions, causing a rush of water through the aquaporins which makes the cells swell and exerts pressure on the skull and spine. This build-up of pressure damages fragile brain and spinal cord tissues, disrupting the flow of electrical signals from the brain to the body and vice versa.

But the scientists discovered that TFP can stop this from happening. Focusing their efforts on important star-shaped brain and spinal cord cells called astrocytes, they found TFP prevents a protein called calmodulin from binding with the aquaporins. Normally, this binding effect sends the aquaporins shooting to the surface of the cell, letting in more water. By halting this action, the permeability of the cells is reduced.

Traditionally, TFP has been used to treat patients with schizophrenia and other mental health conditions. Its long-term use is associated with adverse side effects, but the researchers said their experiments suggested that just a single dose could have a significant long-lasting impact for CNS edema patients.

Since TFP is already licensed for use in humans by the US Federal Drug Administration (FDA) and UK National Institute for Health and Care Excellence (NICE) it could be rapidly deployed as a treatment for brain injuries. But the researchers stressed that further work would allow them to develop new, even better medicines based on their understanding of TFPs properties.

According to the World Health Organisation (WHO), each year around 60 million people sustain a traumatic brain or spinal cord injury and a further 15 million people suffer a stroke. These injuries can be fatal or lead to long-term disability, psychiatric disorders, substance abuse or self-harm.

Professor Roslyn Bill of the Biosciences Research Group at Aston University said:

Every year, millions of people of all ages suffer brain and spinal injuries, whether from falls, accidents, road traffic collisions, sports injuries or stroke. To date, their treatment options have been very limited and, in many cases, very risky.

This discovery, based on a new understanding of how our cells work at the molecular level, gives injury victims and their doctors hope. By using a drug already licensed for human use, we have shown how it is possible to stop the swelling and pressure build-up in the CNS that is responsible for long-term harm.

While further research will help us to refine our understanding, the exciting thing is that doctors could soon have an effective, non-invasive way of helping brain and spinal cord injury patients at their disposal.

Dr. Zubair Ahmed of the University of Birminghams Institute of Inflammation and Ageing said:

This is a significant advance from current therapies, which only treat the symptoms of brain and spinal injuries but do nothing to prevent the neurological deficits that usually occur as a result of swelling. The re-purposed drug offers a real solution to these patients and can be fast-tracked to the clinic.

Dr. Alex Conner of the University of Birminghams Institute of Clinical Sciences said:

It is amazing that our work studying tiny water channels in the brain can tell us something about traumatic brain swelling that affects millions of people every year.

Dr. Mootaz Salman, Research Fellow in Cell Biology at Harvard Medical School, said:

This novel treatment offers new hope for patients with CNS injuries and has huge therapeutic potential. Our findings suggest it could be ready for clinical application at a low cost in the very near future.

Reference: Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema by Philip Kitchen, Mootaz M. Salman, Andrea M. Halsey, Charlotte Clarke-Bland, Justin A. MacDonald, Hiroaki Ishida, Hans J. Vogel, Sharif Almutiri, Ann Logan, Stefan Kreida, Tamim Al-Jubair, Julie Winkel Missel, Pontus Gourdon, Susanna Trnroth-Horsefield, Matthew T. Conner, Zubair Ahmed, Alex C. Conner and Roslyn M. Bill, 14 May 2020, Cell.DOI: 10.1016/j.cell.2020.03.037

Original post:
Cell Pores Discovery Offers New Hope for Millions With Brain and Spinal Cord Injuries - SciTechDaily

Immunai launches with $20M to map the human immune system – VatorNews

The company has already mapped out millions of immune cells and their functions

It hasn't been all that long since we unlocked the human genome, but the effect on healthcare has already been massive. It's even led to a whole new category, personalized medicine, that could very well totally overhaul healthcare we as know it by creating therapies specifically targeted to that specific person.

What if we could do the same thing for our immune system? That's the idea behindImmunai, a company thatlaunched out of stealth on Thursday with $20 million in seed fundingled byViola VenturesandTLV Partners.

The company, founded in December 2018 by ex-Harvard-MIT postdoc researcher Noam Solomon and ex-MIT and Palantir ML engineer Luis Voloch, usesartificial intelligence and machine learning algorithms to better understand the immune system so it can detect, diagnose, and treat disease.

"When I met Luis, I was a math postdoc at MIT and Luis was working to apply machine learning to biology. Together, we wanted to transfer learning methods with AI and define a comprehensive immunological knowledge base. We realized that almost 50 percent of melanoma patients were treated well with immunotherapy, but researchers could not transcend it to lesser-known cancer indications because theres no real database for cancer or immunity," Solomon told VatorNews.

"The main issue here is that all types of diseases, not just cancer, come back to the immune system and how it functions. And, without a comprehensive understanding of the immune system, we wont have highly targeted and effective drugs that actually improve our health."

What does is Immunai can extract over a terabyte of data from a single blood sample. Its database and machine learning algorithms can then be used to map incoming data to hundreds of cell types and states in order to create immune profiles by highlighting differentiated elements. Itsdatabase of immune profiles can be used for biomarker discovery and insight generation, identifying subtle changes in cell type and state-specific expression that can be used to distinguish them from normal expression.

The company has already mapped out millions of immune cells and their functions, building what it says is the largest proprietary data set in the world for clinical immunological data. It can analyze the evolution of disease, including cancer to autoimmune disorders to cardiovascular diseases.

"We combine single-cell biology with AI to provide pharma companies, hospitals, and clinics with a comprehensive understanding of the immune system to better detect, diagnose, and treat disease," said Solomon.

"We have an end-to-end vertically integrated platform on both the lab and computational side that allows us to analyze tens of thousands of genes to build the largest database for immunology to-date."

Right now, no other companies are doing exactly what Immunai is doing, he told me, though companies have been trying to understand the immune system for years. They, however, "have only been looking at two cells, PCR and TCR, and couldnt solve the prohibitive batch problem," while Immunai "can take the complexity of the immune system, simplify it and derive insights from it.

"Were disrupting legacy companies by analyzing 10,000x more data for each cell than they are," Solomon told me.

Immunai hasalready signed seven-figure deals with Fortune 100 pharmaceutical companies, and is helping them accelerate their clinical trials for drugs in the immunotherapy and cell therapy space. It has clinical partnerships with over 10 medical centers, as well as multiple commercial partnerships with cell therapy and checkpoint blockade with biopharma companies. It also has long-term partnerships with research institutions including Upenn, UCSF, Baylor, and others.

The new funding will be used, in part, to expand its team of scientists, engineers, and machine learning experts, which currently consists of 30 employees across New York City, Tel Aviv and San Francisco. It will also be used to build out the company's business functions and further develop its technology.

"The goal is to continue growing our database so that we can apply our learning from one disease to another," Solomon explained.

The company's ultimate mission, he told me, is to "make the biggest impact on healthcare with machine learning by giving researchers and clinicians a better understanding of the immune system."

"We believe this is an incredibly interesting and difficult problem to solve. Weve spent the last year perfecting our technology and building a team of experts across immunology and computer science, so were excited to have this opportunity to grow and make an impact on the next generation of drugs that are being developed.fc"

(Image source:immunai.com)

Read the rest here:
Immunai launches with $20M to map the human immune system - VatorNews

Synthetic Biology Could Lead to Clean Energy Using Light and Carbon… – Labiotech.eu

Researchers in Germany and France have combined synthetic biology with microfluidics to create artificial photosynthetic droplets, which could lead to the production of organic chemicals and clean fuels that is more efficient than nature can achieve alone.

In a study recently published in Science, the research team developed an automated way to produce artificial versions of chloroplasts, the center of photosynthesis in plants. These chloroplasts made within tiny droplets were capable of capturing carbon dioxide using light as much as 100 times more efficiently than previous synthetic biology approaches.

To make these artificial chloroplasts, members of the team at the Max Planck Institute for Terrestrial Microbiology in Germany coupled natural chloroplast membranes from spinach with a synthetic enzymatic module called the CETCH cycle. The CETCH cycle is made up of 18 biocatalysts designed to convert carbon dioxide more efficiently than plants.

These two components were combined in a cell-sized droplet using a microfluidic technology platform with the help of researchers based at the Centre de Recherch Paul Pascal, France.

Our work shows that you can realize alternative, autonomous photosynthetic systems at the microscale from individual biological parts and not by modifying cells through genetic engineering, said Tobias Erb, Professor at the Max Planck Institute for Terrestrial Microbiology, and one of the leaders of the study. This is a step forward towards creating biological systems that show life-like properties from the bottom up.

This synthetic biology technology is currently in its early stages, but the potential applications are limited only by what can be produced by the enzymatic pathway, and the contents of the droplet. For example, this could lead to breakthroughs in biofuel production, or large-scale manufacturing of chemicals like antibiotics.

Currently, this is a proof of principle. There are several challenges to be overcome before we can employ artificial chloroplasts in an industrial setup, Erb explained. Most importantly: stability and robustness of the individual components.

However, if we think about an immediate application, there is huge potential in using our artificial chloroplasts in high-throughput screening of enzymes and prototyping metabolic pathways.

As an example of the immediate commercial potential of the microfluidics platform, another one of the team leaders, Jean-Christophe Baret at the Centre de Recherch Paul Pascal, co-founded the startup Emulseo on the back of similar droplet technology in 2018.

This is not the first attempt at applying synthetic biology to photosynthesis. In a study published last year, the Earth-Life Science Institute in Tokyo constructed artificial cells using minimal components able to supply the energy to drive gene expression in a microcompartment.

They used this energy module to operate one single enzyme, but not a complex metabolic network with multiple reactions like in our case, said Erb. This did not allow the continuous fixation of carbon dioxide into multi-carbon compounds and was notably one to two orders of magnitude slower.

Synthetic biology companies have drawn major investor interest in recent years. One of the latest examples is a 6.4M Series A round raised by the Swedish startup Enginzyme to fund the development of cell-free technology to manufacture plastics and rubber more sustainably than with fossil fuels.

Images from Shutterstock and Synthetic Biology Max Planck Institute for Terrestrial Microbiology:Erb

More here:
Synthetic Biology Could Lead to Clean Energy Using Light and Carbon... - Labiotech.eu

Cell Therapy Shows Promise in Parkinson’s – MedPage Today

Dopaminergic progenitor cells derived from a Parkinson's disease patient's own skin cells and injected into his putamen showed evidence of survival and were associated with improved motor scores and quality of life measures.

The cells were implanted into the 69-year-old Parkinson's patient's putamen in two procedures, left hemisphere followed by right hemisphere, 6 months apart. PET imaging with a dopaminergic activity tracer up to 24 months suggested graft survival, reported Jeffrey Schweitzer, MD, PhD, of Massachusetts General Hospital, and colleagues, in the New England Journal of Medicine.

Over 24 months, the patient's MDS-UPDRS, part III (evaluating parkinsonian motor signs) and PDQ-39 (assessing Parkinson's disease-related quality of life) scores also improved. His Parkinson's drug regimen at 24 months was similar to his pre-procedure treatment, but his levodopa equivalents were reduced from 904 mg to 847 mg.

The patient required no immunosuppression. "We have shown for the first time in this study that these reprogrammed cells are still recognized as self by the patient's immune system and won't be rejected," senior author Kwang-Soo Kim, PhD, of McLean Hospital in Belmont, Massachusetts, said in a statement.

"The study is interesting and promising, but should be interpreted with caution given that it reports on only one patient with limited and incomplete clinical data," noted Malin Parmar, PhD, of Lund University's Developmental and Regenerative Neurobiology department in Sweden, who wasn't involved with the research.

"Nevertheless, it is an important milestone in the field as it reports on survival of stem cell-derived dopamine neurons in a human brain," she told MedPage Today.

"The study takes an autologous approach, where the patient's own cells are used for transplantation," Parmar noted. "It points to the feasibility of such an approach, but also the weaknesses associated with it relating to using different batches of cells for each transplant and each patient, which is likely to result in a high variation in outcome."

Cell replacement has been studied in Parkinson's disease for several decades. Fetal tissue-derived cell transplants have had variable outcomes, due in part to limitations of fetal tissue as a cell source and lack of standardization. Recent advances in developmental and stem cell biology have led to cell-replacement therapies involving dopamine neurons derived from human pluripotent stem cells.

In this study, researchers first performed a skin biopsy on the patient and harvested fibroblasts to generate lines of induced pluripotent stem cells (iPSCs), which were screened for pluripotent differentiation potential and to eliminate potentially harmful mutations.

They identified an iPSC clone capable of becoming midbrain dopaminergic progenitor cells (mDAPs) and guided its differentiation into 28-day mDAPs. The mDAP-derived neurons secreted dopamine and had electrophysiologic properties similar to substantia nigra dopaminergic midbrain neurons. The final cell product used for injection was then treated to eliminate undifferentiated iPSCs and ensure the absence of serotonergic cells that might contribute to graft-induced dyskinesia.

The patient had 4 million cells implanted in his left putamen and a similar injection on the right 6 months later. He was discharged after overnight observation for each procedure.

PET imaging at 24 months showed uptake bilaterally, greater on the right. A semi-quantitative change from baseline was reported as -4.0% to 13.5% on the right, and -4.8% to 9.8% on the left.

The researchers reported no adverse events. Over 24 months, the patient's PDQ-39 score (a quality of life measurement with a scale of 0 to 156; lower scores are better) improved from 62 from the time of his first injection to 2.

"Off" period MDS-UPDRS part III motor scores (on a scale of 0 to 132; higher scores are worse) were 43 at 4 weeks, and improved to 33 at 24 months. "On" motor scores were 38 at the time of first injection, and improved to 29 at 24 months.

Both the patient and raters knew about the intervention and this may have influenced motor and symptom scores, the researchers pointed out. A longer follow-up period may be needed to reach definitive conclusions about graft survival, they added.

"These results reflect the experience of one individual patient and a formal clinical trial will be required to determine if the therapy is effective," Schweitzer noted.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimers, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinsons, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

The research was supported by NIH grants, the philanthropic support of the Parkinson's Cell Therapy Research Fund at McLean Hospital and Massachusetts General Hospital, and the William and Elizabeth Sweet Endowed Professorship in Neuroscience at Harvard Medical School.

Read the original post:
Cell Therapy Shows Promise in Parkinson's - MedPage Today

Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific…

MARSEILLE, France, May 14, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) (Innate or the Company) today announced that it will present new data on its lead partnered asset, monalizumab, at the ASCO20 Virtual Scientific Program being held May 29-31, 2020. The presentation will highlight a Phase II expansion cohort investigating the combination of monalizumab and cetuximab in patients with recurrent or metastatic head and neck squamous cell cancer (R/M SCCHN) who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors (IO-pretreated). Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

We are pleased to present additional data on the combination of monalizumab and cetuximab in head and neck cancer at this years ASCO Virtual Scientific Program. These data further strengthen the encouraging response rates previously reported in our head and neck clinical trial program,commented Pierre Dodion, Chief Medical Officer of Innate Pharma. While the study was not randomized, numerically, these data compare favorably with historical data reported for cetuximab alone or for immuno-oncology (IO) single agent in recurrent or metastatic head and neck cancer after one line of previous systemic therapy.

The poster discussion presentation (#177, abstract #6516), entitled Combination of Monalizumab and Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer Previously Treated with Platinum-based Chemotherapy and PD-(L)1 Inhibitors, will be available on demand beginning at 8 a.m. ET on Friday, May 29 under the Head and Neck Cancer track.

Key Highlights from Phase II Expansion Study Cohort 2 (IO-pretreated)

As of March 2020, 40 platinum and IO-pretreated patients achieved an overall response rate (ORR) of 20%, which confirms the activity previously reported in the post-hoc analysis in the IO-pretreated subgroup in cohort 1 (ORR = 17%, n=18). Responses were observed in platinum-sensitive (3/21) and platinum-resistant patients (5/19), as well as in IO-sensitive (3/17) and IO-resistant patients (5/23), in patients exposed to IO as last previous therapy (5/34) and IO as earlier treatment (3/6).

The combination of monalizumab and cetuximab demonstrated a manageable safety profile, supporting continued investigation. No adverse events led to treatment discontinuation. Seventeen patients (42%) experienced grade 3-4 adverse events. Only one patient (2%) experienced a grade 3-4 adverse event considered related to monalizumab: peripheral sensory neuropathy and asthenia. No treatment-related deaths were reported.

The additional findings from this Phase II study are encouraging and validate the overall response rates previously observed with the combination of monalizumab and cetuximab for the treatment of recurrent or metastatic head and neck cancer, a malignancy with poor prognosis where novel, effective and tolerable therapies continue to be needed for this patient population,said Dr. Roger B. Cohen, Professor of Medicine at the Hospital of the University of Pennsylvania. The dual-targeting action exhibited by the combination of this NKG2A monoclonal antibody, monalizumab, when paired with cetuximab has the potential to provide greater antitumor activity than cetuximab alone, the current standard of care. We look forward to further studies evaluating this novel combination.

As previously disclosed, the start of the Phase III trial of monalizumab in combination with cetuximab in IO-pretreated patients suffering from R/M SCCHN, which will be conducted by AstraZeneca (LSE/STO/NYSE: AZN), is expected in 2020.

About the Monalizumab Phase II Trial

This trial is an open-label, Phase Ib/II study testing monalizumab in combination with cetuximab in patients with R/M SCCHN. The Phase II portion of the trial is comprised of three expansion cohorts:

The primary endpoint for the Phase II portion of the trial is objective response rate. Secondary endpoints for the Phase II portion of the trial include duration of response, progression-free survival and overall survival.

In expansion cohort 1, the combination of monalizumab and cetuximab demonstrated a manageable safety profile and a response rate of 27.5% (36% and 17% in IO-nave and IO-pretreated patients, respectively). Data were presented at the ESMO 2019 Congress. Expansion cohorts 2 and 3 are currently ongoing.

About Monalizumab:

Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed in the cancer cells of many solid tumors and hematological malignancies. Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies.

AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialization agreement initiated in 2015. The ongoing Phase II development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.

About Cetuximab:

Cetuximab is an anti-EGFR monoclonal antibody. NK cells mediate cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) against SCCHN. Genetic and preclinical experiments suggest that ADCC can be enhanced by NK-stimulators.

The activity of cetuximab as a single agent in recurrent and/or metastatic SCCHN is limited, with a 12.6% overall response rate, a median time to progression of 2.3 months and a median overall survival of 5.8 months (Vermorken et al, JCO 2007).

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharmas commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at http://www.innate-pharma.com

Information about Innate Pharma shares:

Disclaimer:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts, the Companys continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Companys business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (AMF), which is available on the AMF website http://www.amf-france.org or on Innate Pharmas website, and public filings and reports filed with the U.S. Securities and Exchange Commission (SEC), including the Companys Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Read the rest here:
Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific...

High Content Screening Market to Witness Growth Acceleration During 2017-2025 – Cole of Duty

Global High Content Screening Market: Snapshot

High-content screening technologies have the ability of simultaneously studying multiple parameters in complex biological systems, a factor that is also one of the key factors driving the global market for high-content screening. Considering the steady rise in the prevalence of various genetic disorders and neurological diseases, the demand for effective screening methods and techniques has significantly increased in the past few years. This scenario has had a positive impact on the global high-content screening market. However, owing to factors such as stringent regulatory framework in many countries, high cost of sophisticated infrastructure, dearth of skilled and trained professionals, and low R&D yields the growth prospects of the market are impaired to a certain extent.

Request Sample of High Content Screening Market Report for more Industry Insights @CLICK HERE NOW

Some of the most popular high-content screening products include flow cytometers, cell imaging systems, consumables, and software. Cell imaging systems have been witnessing strong demand in the recent past, thanks to ongoing advancement in automation and instrumentation techniques. Key end users of high-content screening are industries such as biotechnology and pharmaceutical, government organizations, educational institutions, and contract research organizations (CROs). High-content screening is commonly used by biotechnology and pharmaceutical companies for various clinical and preclinical studies.

High-content screening finds application in target identification and validation, primary and secondary screening, compound profiling, and toxicity studies. High-content screening is mostly used in primary and secondary screening owing to its usage in assessing bioavailability and in qualitative assays. Geographically, North America holds a significant share in the high-content screening market, fueled by a strong regional economy, the presence of sophisticated research and healthcare facilities, and increased focus on overall health and wellbeing.

Global High Content Screening Market: Overview

High-content screening (HCS) refers to a technique used in biological research and drug discovery to discover substances such as peptides, small molecules, or RNAi that change the phenotype of a cell as desired. Phenotypic changes may include increase or decrease in the production of cellular components such as protein and/or alterations in the visual appearance of the cell.

High-content screening merges the molecular tools of cell biology with automated robotic handling, high-resolution microscopy, and automated analysis.

Global High Content Screening Market: Key Trends

The high-content screening market is driven by increasing funding and venture capital investments for cellular research, technological developments in HCS solutions, and cost containment in pharma R&D. However, factors such as high cost of HCS equipment and lack of expert and skilled personnel for operation of equipment are posing a challenge to the markets growth. In addition, inadequate research infrastructure and insufficient funding for R&D in emerging nations is limiting this markets growth.

The high-content screening market is segmented in terms of product, application, end user, and region. In terms of product, instruments, software, consumables, services, and accessories are the segments of this market. The segment of instrument held the leading share of the market in the recent past. The cell imaging and analysis segment held the leading share of the instrument segment of the HCS market. The instrument segment holds the leading share due to advances in instrumentation and automation techniques.

On the basis of application, target identification and validation, toxicity studies, primary and secondary screening, compound profiling, and others are the segments of the HCS market. The segment of primary and secondary screening dominated the market in the recent past. The dominance of this segment is due to its large-scale usage in qualitative assays for lead specificity, evaluation of bioavailability, and exclusion of compounds with unintended modes of action.

In terms of end user, the HCS market is segmented into academic and government institutes, pharmaceutical and biotechnology companies, and contract research organizations. The segment of pharmaceutical and biotechnology companies held the leading share of the global HCS market in the recent past. The dominance of this segment is owing to the extensive usage of HCS in preclinical and clinical studies in the biotechnology and pharmaceutical industries.

Global High Content Screening Market: Market Potential

Beyond its conventional application in biological resaerch, high-content screening is being used in studying fat accumulation in cells. Researchers at the Department of Environmental Science at University of Georgia College of Public Health carried out studies to determine how exposure to phthalates in the form of nail polish or soap is related to the amount of fat stored in our bodies.

High-content screening employs image processing algorithms and computer machine language to measure multiple parameters objectively in no time.

Global High Content Screening Market: Regional Outlook

North America is the leading market for high-content screening trailed by the regions of Europe, Asia Pacific, Latin America, and the Middle East and Africa. High research and development expenditures, government support for research initiatives, and the presence of leading lifescience market players are attributed to the dominance of North America high content screening market.

Get TOC of High Content Screening Market Report for more Industry Insights @CLICK HERE NOW

Global High Content Screening Market: Competitive Landscape

The key players in the global high content screening market includeGE Healthcare, PerkinElmer Inc., Becton, Dickinson and Company, Danaher Corporation, and Thermo Fisher Scientific Inc. Some other players in the market include BioTek Instruments Inc., Tecan Group Ltd., Merck Millipore, Bio-rad Laboratories Inc, and Yokogawa Electric Corporation.

See the original post here:
High Content Screening Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty